Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
RESEARCH TOOLSreports
CRSP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.52 - $91.10
Previous CloseN/A
Volume437.82K
Average Volume (3M)2.47M
Market Cap
$4.48B
Enterprise Value$2.30B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.24
Next Earnings
May 12, 2025EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.36
Shares Outstanding85,774,475
10 Day Avg. Volume3,385,828
30 Day Avg. Volume2,467,906
Standard Deviation0.19
R-Squared0.21
Alpha-0.00753
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)120.04
Price to Cash Flow (P/CF)-22.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit61.54
Enterprise Value/Ebitda-5.13
Forecast
1Y Price Target
$70.25Price Target Upside32.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe in-house manufacturing capability and $1.9 billion of cash provide a strong financial and operational foundation for CRSP.
Pipeline DevelopmentCRSP's diverse pipeline, including Casgevy and second-generation allogeneic products, supports an Outperform rating.
Product ApprovalsThe Casgevy launch is expected to accelerate due to approvals in the UAE and anticipated approvals in Kuwait and Qatar.
Bears Say
Clinical Trial DelaysExcitement for CTX320 data has tempered somewhat following the delay of NVS' HORIZON trial.
Market PerformanceCasgevy launch was slower than Street expectations, causing a reduction in the price target.
Product Launch ChallengesUptake has been slow due to the intense commitment of the myeloablation conditioning regimen and the permanent nature and novelty of gene editing.
---
Ownership Overview
1.65% Insiders
16.44% Mutual Funds
46.33% Other Institutional Investors
18.43% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $36.52 and its highest was $91.10 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Crispr Therapeutics AG’s market cap is $4.48B.
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is May 12, 2025 which is in 81 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on Feb 11, 2025. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$1.201 by $0.761.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -1.24.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 85,774,475 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$0.44 in its last earnings report, beating expectations of -$1.201. Following the earnings report the stock price went up 9.288%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Currently, no hedge funds are holding shares in CRSP
---
Crispr Therapeutics AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.25 (32.50% Upside)
$70.25 (32.50% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 94%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.51%
12-Months-Change
Fundamentals
Return on Equity
-18.96%
Trailing 12-Months
Asset Growth
0.56%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
CRSP Stock 12 Month Forecast
Average Price Target
$70.25
▲(32.50% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering CRSP
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+20.19%
initiated a buy rating 7 months ago
Copying Anthony Butler's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +20.19% per trade.
---